Close Menu

NEW YORK – Adaptive Biotechnologies said this week that it has identified a diagnostically useful T cell profile for Lyme disease. 

It's an important early step in developing immunoSeq Dx, a single clinical assay that the Seattle-based immune sequencing company intends to be able to use as a diagnostic for infectious disease, autoimmune disease, and cancer.

On a conference call with investors, company officials said they've begun discussions with the US Food and Drug Administration on how to get regulatory approval for their ultimate vision of a multi-faceted test.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.